Sanofi-aventis

Sanofi-aventis Announces that Jevtana® (cabazitaxel) Injection Is Now Available in the U.S.

Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]

By |2017-10-19T10:53:46-04:00July 20th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Financial, Uncategorized, Understanding APC|18 Comments
Read More

On The Horizon – A Status Report of Six New Promising Advancing Treatments for Men with Advanced Prostate Cancer as of the Beginning of June, 2010

As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]

By |2010-06-08T09:15:34-04:00June 8th, 2010|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), Cabazitaxel, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, General Information, Hormone Therapy, MDV3100, On The Horizon, Prostate Ponderings, Prostvac, Research, TAK700, Uncategorized, Understanding APC|3 Comments
Read More
Go to Top